Literature DB >> 9741839

Plasma disappearance of exogenous erythropoietin in mice under different experimental conditions.

C E Lezón1, M P Martínez, M I Conti, C E Bozzini.   

Abstract

Erythropoietin (EPO) is a glycoprotein hormone produced primarily in the kidneys and to a lesser extent in the liver that regulates red cell production. Most of the studies conducted in experimental animals to assess the role of EPO in the regulation of erythropoiesis were performed in mouse models. However, little is known about the in vivo metabolism of the hormone in this species. The present study was thus undertaken to measure the plasma tl/2 of radiolabeled recombinant human EPO (rh-EPO) in normal mice as well as in mice with altered erythrocyte production rates (EPR), plasma EPO (pEPO) titer, marrow responsiveness, red cell volume, or liver function. Adult CF-1 mice of both sexes were used throughout. For the EPO life-span studies, 30 mice in each experiment were intravenously injected with 600,000 cpm of 125l-rh-EPO and bled by cardiac puncture in groups of five every hour for 6 h. Trichloroacetic acid (TCA) was added to each plasma sample and the radioactivity in the precipitate measured in a gamma-counter. EPO, pEPO, marrow responsiveness, or red cell volume were altered by either injections of rh-EPO, 5-fluorouracil, or phenylhydrazine, or by bleeding, or red cell transfusion. Liver function was altered by CI4C administration. In the normal groups of mice, the estimated tl/2 was 182.75+/-14.4 (SEM) min. The estimated tl/2 of the other experimental groups was not significantly different from normal. These results, therefore, strongly suggest that the clearance rate of EPO in mice is not subjected to physiologic regulation and that pEPO titer can be really taken as the reflection of the EPO production rate, at least in the experimental conditions reported here.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9741839     DOI: 10.1385/ENDO:8:3:331

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.925


  16 in total

1.  THE METABOLISM OF ERYTHROPOIETIN IN PATIENTS WITH ANEMIA DUE TO DEFICIENT ERYTHROPOIESIS.

Authors:  W F ROSSE; T A WALDMANN
Journal:  J Clin Invest       Date:  1964-07       Impact factor: 14.808

2.  The in vivo metabolism of recombinant human erythropoietin in the rat.

Authors:  J L Spivak; B B Hogans
Journal:  Blood       Date:  1989-01       Impact factor: 22.113

3.  Studies on medullary and extramedullary erythropoiesis in the adult mouse.

Authors:  C E Bozzini; M E Barrio Rendo; F C Devoto; C E Epper
Journal:  Am J Physiol       Date:  1970-09

4.  Quantitation of specific binding of erythropoietin to human erythroid colony-forming cells.

Authors:  K Sawada; S B Krantz; S T Sawyer; C I Civin
Journal:  J Cell Physiol       Date:  1988-11       Impact factor: 6.384

5.  Average life of the erythropoietin molecule in the circulation as evidenced by parabiosis.

Authors:  C E Bozzini
Journal:  Acta Physiol Lat Am       Date:  1966

6.  Erythropoietin life span in rats with hypoplastic and hyperplastic bone marrows.

Authors:  E Piroso; A J Erslev; K K Flaharty; J Caro
Journal:  Am J Hematol       Date:  1991-02       Impact factor: 10.047

7.  Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men.

Authors:  K K Flaharty; J Caro; A Erslev; J J Whalen; E M Morris; T D Bjornsson; P H Vlasses
Journal:  Clin Pharmacol Ther       Date:  1990-05       Impact factor: 6.875

8.  Comparative pharmacokinetics and distribution of human urinary erythropoietin and recombinant human erythropoietin in rats.

Authors:  H Kinoshita; N Ohishi; M Kato; S Tokura; A Okazaki
Journal:  Arzneimittelforschung       Date:  1991-09

9.  Higher erythropoietin secretion in response to cobaltous chloride in post-hypoxic than in hypertransfused polycythemic mice.

Authors:  R M Alippi; P Boyer; T Leal; A C Barcelò; M P Martinez; C E Bozzini
Journal:  Haematologica       Date:  1992 Nov-Dec       Impact factor: 9.941

10.  Binding and internalization of recombinant human erythropoietin in murine erythroid precursor cells.

Authors:  R A Mufson; T G Gesner
Journal:  Blood       Date:  1987-05       Impact factor: 22.113

View more
  2 in total

Review 1.  Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease.

Authors:  Robert Deicher; Walter H Hörl
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Pharmacodynamics of recombinant human erythropoietin in murine bone marrow.

Authors:  Peter J Bugelski; Thomas Nesspor; Amy Volk; Joanne O'Brien; Dorie Makropoulos; Kim Shamberger; Paul W Fisher; Ian James; Danielle Graden; Renold J Capocasale
Journal:  Pharm Res       Date:  2007-07-04       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.